Skip to content

Exploring new treatment techniques for refractory auditory hallucinations in schizophrenia based on transcranial direct current stimulation

Exploring new treatment techniques for refractory auditory hallucinations in schizophrenia based on transcranial direct current stimulation

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200055191
Enrollment
Unknown
Registered
2022-01-02
Start date
2022-04-01
Completion date
Unknown
Last updated
2023-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

Active-tDCS group:Active-tDCS
Sham-tDCS group:Sham-tDCS

Sponsors

Shanghai Mental Health Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Inpatients with schizophrenia in Shanghai Mental Health Center; 2. Meet the diagnostic criteria of DSM-5 for schizophrenia; 3. Aged between 18 and 55; 4. After 6 weeks of treatment with two or more antipsychotic drugs (400-600 mg/day equivalent dose of CPZ), the symptoms of auditory hallucinations are still not relieved (Audio hallucination rating scale (AHRS) total score> 18 points); 5. Patients and their families signed a written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with organic brain diseases, patients with psychoactive substances or alcohol dependence, patients with epilepsy and intellectual disabilities; 2. Suffering from severe or unstable physical diseases, or abnormal laboratory tests and judged to be clinically significant, the researchers believe that it affects the safety of the patients; 3. Contraindications for tDCS: intracranial metal foreign body, cochlear implant, intracranial hypertension; 4. Those who have received ECT within 6 months; 5. Pregnant, lactating patients, women of childbearing age with positive urine HCG test results during the screening period; 6. Patients with obvious negative impulses and disordered behaviors who cannot cooperate with the examination; 7. The investigator believes that there are other circumstances that are not suitable for participating in the clinical trial.

Design outcomes

Primary

MeasureTime frame
Auditory Hallucination Rating Scale (AHRS) Score;

Secondary

MeasureTime frame
Calgary Depression Scale for Schizophrenia (CDSS) Score;CogState Cognitive Function Assessment;UPSA-B Social Function Assessment;Multimodal magnetic resonance imaging;Inflammatory cytokines;

Countries

China

Contacts

Public ContactZhang Yi

Shanghai Mental Health Center

jeanzy@163.com+86 18017311217

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026